Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

Bookmark and Share
Published: 4 May 2021
Views: 220
Rating:
Save
Dr Giulia Pasello - University of Padova, Padua, Italy

Dr Giulia Pasello speaks to ecancer about her multi-centre real-world study investigating the efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab.

Initially, she explains the rationale of her study. Dr Pasello then discusses the methodology and key results from this study. In the end, she talks about the impact these results can have on the treatment of NSCLC in the future.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.